Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.

Surmont V, Aerts JG, van Klaveren RJ, Tournoy K, Tan KY, Vernhout RM, Schmitz PI, Legrand C, Hoogsteden HC, van Meerbeeck JP.

Oncology. 2010;78(3-4):267-70. doi: 10.1159/000315733. Epub 2010 Jun 7.

PMID:
20523087
2.

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.

Wang LR, Huang MZ, Zhang GB, Xu N, Wu XH.

Cancer Chemother Pharmacol. 2007 Sep;60(4):601-7. Epub 2007 Jun 5.

PMID:
17549479
3.

Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.

Paccagnella A, Oniga F, Bearz A, Favaretto A, Clerici M, Barbieri F, Riccardi A, Chella A, Tirelli U, Ceresoli G, Tumolo S, Ridolfi R, Biason R, Nicoletto MO, Belloni P, Veglia F, Ghi MG.

J Clin Oncol. 2006 Feb 1;24(4):681-7. Erratum in: J Clin Oncol. 2006 May 10;24(14):2220.

PMID:
16446341
4.

Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.

Thomas P, Robinet G, Ferri-Dessens RM, Léna H, Gouva S, Vernejoux JM, Kleisbauer JP.

Lung Cancer. 2002 May;36(2):191-8.

PMID:
11955654
5.

Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.

Obasaju CK, Ye Z, Bloss LP, Monberg MJ, Curiel RE.

Clin Lung Cancer. 2005 Nov;7(3):202-7.

PMID:
16354316
6.

Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.

Yoshimura M, Imamura F, Ueno K, Uchida J.

Clin Lung Cancer. 2006 Nov;8(3):208-13.

PMID:
17239297
7.

A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.

Ng EW, Sandler AB, Robinson L, Einhorn LH.

Am J Clin Oncol. 1999 Dec;22(6):550-3.

PMID:
10597737
8.

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.

Soo RA, Lim HL, Wang LZ, Lee HS, Millward MJ, Tok LT, Lee SC, Lehnert M, Goh BC.

Cancer Chemother Pharmacol. 2003 Aug;52(2):153-8. Epub 2003 May 16.

PMID:
12750842
9.

A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).

Schallier D, Neyns B, Fontaine C, Steene JV, De Mey J, Meysman M, De Grève J.

Lung Cancer. 2007 May;56(2):247-54. Epub 2007 Mar 6.

PMID:
17337086
10.

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).

Thomas P, Robinet G, Gouva S, Fournel P, Léna H, Le Caer H, Perol M, Berard H, Bombaron P, Vergnenegre A, Kleisbauer JP; Groupe français de pneumo-cancérologie..

Lung Cancer. 2006 Jan;51(1):105-14. Epub 2005 Nov 28.

PMID:
16310886
11.

Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.

Abratt RP, Sandler A, Crinò L, Steward WP, Shepherd FA, Green MR, Nguyen B, Peters GJ.

Semin Oncol. 1998 Aug;25(4 Suppl 9):35-43.

PMID:
9728583
12.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
13.

[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].

Sumiyoshi H, Yamasaki M, Doi M, Maeda H, Kuwabara M, Miyamoto S, Fukuhara K.

Gan To Kagaku Ryoho. 2006 Jun;33(6):773-7. Japanese.

PMID:
16770095
14.

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.

Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL.

Lung Cancer. 2001 May;32(2):189-96.

PMID:
11325490
15.

Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.

Saito H, Nakagawa K, Takeda K, Iwamoto Y, Ando M, Maeda M, Katakami N, Nakano T, Kurata T, Fukuoka M.

Am J Clin Oncol. 2012 Feb;35(1):58-63. doi: 10.1097/COC.0b013e318201a0f3.

PMID:
21293243
16.

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.

Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S, Matsui K, Kashii T, Takada M, Nakanishi Y, Kato T, Fukuoka M; West Japan Thoracic Oncology Group (WJTOG)..

Cancer. 2006 Aug 1;107(3):599-605.

17.

A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.

Tomizawa Y, Ishihara S, Iijima H, Imai H, Sato K, Yatomi M, Iwasaki Y, Yamada H, Kobayashi G, Ishida E, Inoue T, Aoki H, Watanabe S, Kawashima O, Mori M, Saito R.

Am J Clin Oncol. 2007 Oct;30(5):498-502.

PMID:
17921710
18.

Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.

Hainsworth JD, Burris HA 3rd, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC Jr, Smith SW, Greco FA.

Cancer. 1999 Mar 15;85(6):1269-76.

PMID:
10189131
20.

A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.

Ricci S, Antonuzzo A, Galli L, Tibaldi C, Bertuccelli M, Lopes Pegna A, Petruzzelli S, Bonifazi V, Orlandini C, Franco Conte P.

Cancer. 2000 Oct 15;89(8):1714-9.

PMID:
11042565

Supplemental Content

Support Center